Raymond James & Associates’s Accendra Health ACH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,817
| Closed | -$743K | – | 4021 |
|
|
2022
Q3 | $743K | Sell |
30,817
-1,821
| -6% | -$56.1K | ﹤0.01% | 2577 |
|
|
2022
Q2 | $1.03M | Buy |
32,638
+1,295
| +4% | +$46.9K | ﹤0.01% | 2426 |
|
|
2022
Q1 | $1.38M | Sell |
31,343
-8,607
| -22% | -$370K | ﹤0.01% | 2389 |
|
|
2021
Q4 | $1.74M | Sell |
39,950
-1,156
| -3% | -$45.3K | ﹤0.01% | 2270 |
|
|
2021
Q3 | $1.29M | Sell |
41,106
-5,722
| -12% | -$225K | ﹤0.01% | 2409 |
|
|
2021
Q2 | $1.98M | Buy |
46,828
+12,061
| +35% | +$469K | ﹤0.01% | 2103 |
|
|
2021
Q1 | $1.31M | Buy |
34,767
+5,130
| +17% | +$160K | ﹤0.01% | 2312 |
|
|
2020
Q4 | $802K | Buy |
29,637
+11,868
| +67% | +$305K | ﹤0.01% | 2483 |
|
|
2020
Q3 | $446K | Sell |
17,769
-134
| -0.7% | -$1.95K | ﹤0.01% | 2710 |
|
|
2020
Q2 | $136K | Hold |
17,903
| – | – | ﹤0.01% | 3228 |
|
|
2020
Q1 | $164K | Sell |
17,903
-906
| -5% | -$5.47K | ﹤0.01% | 3104 |
|
|
2019
Q4 | $97K | Sell |
18,809
-1,041
| -5% | -$6.68K | ﹤0.01% | 3481 |
|
|
2019
Q3 | $115K | Sell |
19,850
-394
| -2% | -$1.77K | ﹤0.01% | 3372 |
|
|
2019
Q2 | $65K | Buy |
20,244
+72
| +0.4% | +$246 | ﹤0.01% | 3475 |
|
|
2019
Q1 | $83K | Buy |
20,172
+956
| +5% | +$6.05K | ﹤0.01% | 3425 |
|
|
2018
Q4 | $122K | Sell |
19,216
-2,718
| -12% | -$28.2K | ﹤0.01% | 3270 |
|
|
2018
Q3 | $362K | Sell |
21,934
-407
| -2% | -$6.92K | ﹤0.01% | 2920 |
|
|
2018
Q2 | $373K | Sell |
22,341
-34,786
| -61% | -$563K | ﹤0.01% | 2877 |
|
|
2018
Q1 | $888K | Buy |
57,127
+7,372
| +15% | +$131K | ﹤0.01% | 2215 |
|
|
2017
Q4 | $939K | Sell |
49,755
-624,506
| -93% | -$13.8M | ﹤0.01% | 2160 |
|
|
2017
Q3 | $19.7M | Sell |
674,261
-5,907
| -0.9% | -$174K | 0.04% | 456 |
|
|
2017
Q2 | $21.9M | Buy |
680,168
+8,942
| +1% | +$293K | 0.05% | 389 |
|
|
2017
Q1 | $23.2M | Buy |
671,226
+13,826
| +2% | +$494K | 0.05% | 341 |
|
|
2016
Q4 | $23.2M | Buy |
657,400
+3,602
| +0.6% | +$122K | 0.06% | 321 |
|
|
2016
Q3 | $22.7M | Buy |
653,798
+35,821
| +6% | +$1.25M | 0.06% | 309 |
|
|
2016
Q2 | $23.1M | Buy |
617,977
+30,420
| +5% | +$1.14M | 0.07% | 279 |
|
|
2016
Q1 | $23.7M | Buy |
587,557
+7,517
| +1% | +$280K | 0.08% | 267 |
|
|
2015
Q4 | $20.9M | Sell |
580,040
-28,053
| -5% | -$1.01M | 0.07% | 298 |
|
|
2015
Q3 | $19.4M | Sell |
608,093
-5,503
| -0.9% | -$187K | 0.08% | 275 |
|
|
2015
Q2 | $20.9M | Buy |
613,596
+46,235
| +8% | +$1.56M | 0.08% | 281 |
|
|
2015
Q1 | $19.2M | Buy |
567,361
+100,909
| +22% | +$3.52M | 0.08% | 265 |
|
|
2014
Q4 | $16.4M | Buy |
466,452
+15,746
| +3% | +$530K | 0.08% | 272 |
|
|
2014
Q3 | $14.8M | Buy |
450,706
+19,582
| +5% | +$666K | 0.08% | 255 |
|
|
2014
Q2 | $14.7M | Buy |
431,124
+32,159
| +8% | +$1.1M | 0.09% | 236 |
|
|
2014
Q1 | $14M | Buy |
398,965
+26,631
| +7% | +$940K | 0.1% | 229 |
|
|
2013
Q4 | $13.6M | Buy |
372,334
+26,978
| +8% | +$990K | 0.1% | 216 |
|
|
2013
Q3 | $11.9M | Buy |
345,356
+18,586
| +6% | +$650K | 0.1% | 208 |
|
|
2013
Q2 | $11.1M | Buy |
+326,770
| New | +$10.8M | 0.1% | 213 |
|
Other funds holding ACH
Raymond James & Associates's ACH Position: Q4 2022 in Review
Raymond James & Associates sold out of Accendra Health (ACH) in Q4 2022, closing a stake of 30,817 shares — an estimated $743K sold.
Raymond James & Associates first reported a position in ACH in Q2 2013 and held it in 38 quarters. The position peaked at $23.7M in Q1 2016. 219 funds tracked by Wall St. Rank hold ACH as of Q4 2022.
- Raymond James & Associates reported no remaining Accendra Health position as of Q4 2022 after selling out during the quarter.
- Raymond James & Associates sold 30,817 Accendra Health shares in Q4 2022, an estimated $743K.
- Raymond James & Associates first reported a position in Accendra Health in Q2 2013 and held it in 38 quarters.
- Raymond James & Associates's Accendra Health position peaked at $23.7M in Q1 2016.
- 219 funds tracked by Wall St. Rank held Accendra Health as of Q4 2022.
Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.